Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.50 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | UBE2I | P63279 | 1/20 | 0.45 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.45 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714638 | 0.88 | TTR (0.51) | SNCAHKDC1KDM1AMAPTCDC25B | |
| SCHEMBL28790106 | 0.87 | SNCA (0.57) | SNCAHKDC1KDM1AMAPTKDM4E | |
| SCHEMBL31389122 | 0.84 | HKDC1 (0.49) | SNCAHKDC1KDM1AMAPTCDC25B | |
| SCHEMBL28790103 | 0.82 | TNNI3 (0.45) | SNCAHKDC1MAPTCDC25BKDM4E | |
| SCHEMBL1715599 | 0.80 | MEN1 (0.45) | HKDC1MAPTSAE1UBA2KDM4E | |
| SCHEMBL29864695 | 0.80 | MEN1 (0.45) | HKDC1MAPTSAE1UBA2KDM4E | |
| SCHEMBL8928013 | 0.79 | MAPT (0.40) | HKDC1KDM1AMAPTKDM4EMEN1 | |
| SCHEMBL8333457 | 0.78 | HKDC1 (0.41) | HKDC1KDM1AMAPTKDM4EMEN1 | |
| SCHEMBL5051397 | 0.77 | SNCA (0.53) | SNCAHKDC1KDM1AMAPTCDC25B | |
| SCHEMBL5073467 | 0.77 | SNCA (0.51) | SNCAHKDC1KDM1AMAPTCDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12458605-B2 | Lipid nanoparticle | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2025-11-04 | — | — | US | disclosed |
| WO-2025129333-A1 | LIPID NANOPARTICLES HAVING NON-POLAR LIPIDS FOR NUCLEIC ACID DELIVERY TO THE LIVER | NANOVATION THERAPEUTICS INC. (CA) | 2025-06-26 | — | — | WO | disclosed |
| WO-2024216026-A1 | COMPOSITIONS AND METHODS FOR DELIVERING CARGO TO CELLS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240024252-A1 | LIPID NANOPARTICLE | NITTO DENKO CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| WO-2023191050-A1 | PHARMACEUTICAL COMPOSITION FOR DELIVERY TO CANCER, OR IMMUNOSTIMULATING COMPOSITION | 日東電工株式会社 | 2023-10-05 | — | — | WO | disclosed |
| EP-4223314-A1 | LIPID NANOPARTICLE | National University Corporation Hokkaido University (JP) | 2023-08-09 | — | — | EP | disclosed |
| CN-116367718-A | Lipid nanoparticles | 国立大学法人北海道大学 | 2023-06-30 | — | — | CN | disclosed |
| US-11666534-B2 | Methods of administering lipid formulations with viral immunogens | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-06-06 | — | — | US | disclosed |
| WO-2022071582-A1 | LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2022-04-07 | — | — | WO | disclosed |
| EP-3676394-A1 | NICKING AND EXTENSION AMPLIFICATION REACTION (NEAR) OF RESPIRATORY SYNCYTIAL VIRUS SPECIES | Ionian Technologies Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046610-A1 | NICKING AND EXTENSION AMPLIFICATION REACTION (NEAR) OF RESPIRATORY SYNCYTIAL VIRUS SPECIES | IONIAN TECHNOLOGIES INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2011081896-A2 | PLASMONIC ELECTRICITY | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024252-A1 | LIPID NANOPARTICLE | LIPC, ACOX1, ABCB4 | SNCA 2921/4885HKDC1 2037/4885KDM1A 3455/4885 |
| US-12458605-B2 | Lipid nanoparticle | LIPC, ACOX1, ABCB4 | SNCA 2926/4885HKDC1 2148/4885KDM1A 3492/4885 |
| US-11666534-B2 | Methods of administering lipid formulations with viral immunogens | STING1, CGAS, PLA2G2A | SNCA 4380/4885HKDC1 3736/4885KDM1A 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.